FGF23 and X-linked hypophosphatemic rickets: Similarly, the administration of a modified anti-FGF23 antibody (burosumab) in patients with X-linked hypophosphatemic rickets, a disease with constantly elevated FGF23 levels, also led to elevated serum phosphate and 1,25(OH)2D levels [58].